151 related articles for article (PubMed ID: 37712859)
1. 'Immunization during ART and ATI for HIV-1 vaccine discovery/development'.
Stamatatos L
Curr Opin HIV AIDS; 2023 Nov; 18(6):309-314. PubMed ID: 37712859
[TBL] [Abstract][Full Text] [Related]
2. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
3. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
Malherbe DC; Wibmer CK; Nonyane M; Reed J; Sather DN; Spencer DA; Schuman JT; Guo B; Pandey S; Robins H; Park B; Fuller DH; Sacha JB; Moore PL; Hessell AJ; Haigwood NL
Front Immunol; 2020; 11():984. PubMed ID: 32582155
[TBL] [Abstract][Full Text] [Related]
4. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
[TBL] [Abstract][Full Text] [Related]
5. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.
Hoot S; McGuire AT; Cohen KW; Strong RK; Hangartner L; Klein F; Diskin R; Scheid JF; Sather DN; Burton DR; Stamatatos L
PLoS Pathog; 2013 Jan; 9(1):e1003106. PubMed ID: 23300456
[TBL] [Abstract][Full Text] [Related]
6. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.
Williams WB; Wiehe K; Saunders KO; Haynes BF
J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25831. PubMed ID: 34806332
[TBL] [Abstract][Full Text] [Related]
7. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
[TBL] [Abstract][Full Text] [Related]
8. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.
McGuire AT; Hoot S; Dreyer AM; Lippy A; Stuart A; Cohen KW; Jardine J; Menis S; Scheid JF; West AP; Schief WR; Stamatatos L
J Exp Med; 2013 Apr; 210(4):655-63. PubMed ID: 23530120
[TBL] [Abstract][Full Text] [Related]
9. Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer.
Lee JH; Nakao C; Appel M; Le A; Landais E; Kalyuzhniy O; Hu X; Liguori A; Mullen TM; Groschel B; Abbott RK; Sok D; Schief WR; Crotty S
Cell Rep; 2022 Mar; 38(10):110485. PubMed ID: 35263576
[TBL] [Abstract][Full Text] [Related]
10. Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.
Leaman DP; Stano A; Chen Y; Zhang L; Zwick MB
J Virol; 2021 Jun; 95(13):e0000521. PubMed ID: 33883221
[TBL] [Abstract][Full Text] [Related]
11. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
[TBL] [Abstract][Full Text] [Related]
12. Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates.
Ding X; Cao K; Wang J; Wan Y; Chen Q; Ren Y; Zheng Y; Zhu M; Tian R; Wang W; Zhao C; Zhang X; Xu J
Virol Sin; 2021 Aug; 36(4):784-795. PubMed ID: 33723807
[TBL] [Abstract][Full Text] [Related]
13. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
14. Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors.
Willis JR; Berndsen ZT; Ma KM; Steichen JM; Schiffner T; Landais E; Liguori A; Kalyuzhniy O; Allen JD; Baboo S; Omorodion O; Diedrich JK; Hu X; Georgeson E; Phelps N; Eskandarzadeh S; Groschel B; Kubitz M; Adachi Y; Mullin TM; Alavi NB; Falcone S; Himansu S; Carfi A; Wilson IA; Yates JR; Paulson JC; Crispin M; Ward AB; Schief WR
Immunity; 2022 Nov; 55(11):2149-2167.e9. PubMed ID: 36179689
[TBL] [Abstract][Full Text] [Related]
15. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.
Virnik K; Nesti E; Dail C; Scanlan A; Medvedev A; Vassell R; McGuire AT; Stamatatos L; Berkower I
Vaccine; 2018 Aug; 36(34):5166-5172. PubMed ID: 30037665
[TBL] [Abstract][Full Text] [Related]
16. Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env.
Escolano A; Gristick HB; Gautam R; DeLaitsch AT; Abernathy ME; Yang Z; Wang H; Hoffmann MAG; Nishimura Y; Wang Z; Koranda N; Kakutani LM; Gao H; Gnanapragasam PNP; Raina H; Gazumyan A; Cipolla M; Oliveira TY; Ramos V; Irvine DJ; Silva M; West AP; Keeffe JR; Barnes CO; Seaman MS; Nussenzweig MC; Martin MA; Bjorkman PJ
Sci Transl Med; 2021 Nov; 13(621):eabk1533. PubMed ID: 34818054
[TBL] [Abstract][Full Text] [Related]
17. Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms.
Murji AA; Qin JS; Hermanus T; Morris L; Georgiev IS
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372503
[TBL] [Abstract][Full Text] [Related]
18. Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1.
Liao HX; Tsao CY; Alam SM; Muldoon M; Vandergrift N; Ma BJ; Lu X; Sutherland LL; Scearce RM; Bowman C; Parks R; Chen H; Blinn JH; Lapedes A; Watson S; Xia SM; Foulger A; Hahn BH; Shaw GM; Swanstrom R; Montefiori DC; Gao F; Haynes BF; Korber B
J Virol; 2013 Apr; 87(8):4185-201. PubMed ID: 23365441
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.
de Taeye SW; Moore JP; Sanders RW
Trends Immunol; 2016 Mar; 37(3):221-232. PubMed ID: 26869204
[TBL] [Abstract][Full Text] [Related]
20. Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation.
Nguyen HT; Qualizza A; Anang S; Zhao M; Zou S; Zhou R; Wang Q; Zhang S; Deshpande A; Ding H; Chiu TJ; Smith AB; Kappes JC; Sodroski JG
J Virol; 2022 Apr; 96(8):e0166821. PubMed ID: 35343783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
